Adverse events (randomisation to post‐treatment) · children and adolescents with anxiety disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (randomisation to post‐treatment) · children and adolescents with anxiety disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Infant Grade 3/4 Severe Adverse Events · HIV‐Infected Pregnant Women With CD4 Counts >200 cells/mm3
Mma Bana: AZT/3TC/LPV‐r showed no clear difference in infants With Any Grade 3/4 Severe Adverse Events compared with AZT/3TC/ABC (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults (aged 18+) with colorectal cancer
It is very uncertain whether adjunctive Coriolus versicolor changes withdrawal from treatment due to adverse events ‐ compared with no adjunctive treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: number of moderate adverse events · adults and children with cystic fibrosis and P aeruginosa
The intervention showed no clear difference in adverse events: number of moderate adverse events (moderate certainty).
1 finding from 1 review
Adverse reaction: cardiac arrest Number of events · neonates receiving EBT
1 finding from 1 review
Intervention not reported
Severe adverse events: raised alkaline phosphatase · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: raised alkaline phosphatase (low certainty).
1 finding from 1 review
Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: number of any adverse event reported · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: tobramycin for inhalation powder showed no clear difference in adverse events: number of any adverse event reported compared with tobramycin (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events: a. hypoglycaemia (% of participants)
1 finding from 1 review
Adverse drug events · people with ADHD and epilepsy
Omega‐3 (with risperidone and previous ASM) showed no clear difference in proportion of people experiencing adverse drug events compared with risperidone and previous ASM only (low certainty).
1 finding from 1 review
Adverse drug events · people with ADHD and epilepsy
1 finding from 1 review
Adverse events at 4 weeks; 1085 participants (8 RCTs) · cervical dystonia
Botulinum toxin type A probably leads to higher adverse events at 4 weeks; 1085 participants (8 RCTs) compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.23 [1.05, 1.43]
Studies not reported
Moderate
Adverse events (hot flushes) · women with uterine fibroids
1 finding from 1 review
Non‐serious adverse events: total bilirubin elevation · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: total bilirubin elevation compared with TACE (very low certainty).
1 finding from 1 review
Withdrawal due to serious adverse events Not reported · patients with rheumatoid arthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grade 5 adverse events (excluding progressive disease) · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
Next‐generation ALK inhibitor showed no clear difference in grade 5 adverse events (excluding progressive disease) compared with crizotinib (low certainty).
1 finding from 1 review
Withdrawals due to adverse outcomes · atopic eczema
1 finding from 1 review